Q1 2025 Jaguar Health Inc Earnings Call Transcript
Key Points
- Increased demand for Mytesi, with dispensed prescriptions rising by approximately 2% in Q1 2025 compared to Q1 2024.
- Initial proof-of-concept results for crofelemer showed a reduction in TPN by up to 27% for MVID patients and 12.5% for pediatric SBS patients, indicating potential for disease progression modification.
- Jaguar Health Inc (JAGX) has orphan designation for both short bowel syndrome and MVID, which may allow for expedited regulatory approval pathways.
- The company is engaged in multiple ongoing trials, including two placebo-controlled Phase II trials for MVID and SBS, with results expected in the first half of 2026.
- Significant results in adult breast cancer patients from the OnTarget study, with crofelemer achieving statistically significant results in a prespecified subgroup, leading to a Type C meeting with the FDA to discuss regulatory pathways.
- Net revenue decreased by approximately 6% in Q1 2025 compared to Q1 2024, and by 37% compared to Q4 2024.
- Loss from operations increased by $1.2 million from Q1 2024 to Q1 2025, indicating rising operational costs.
- Non-GAAP recurring EBITDA showed a net loss of $9.7 million in Q1 2025, up from $8.8 million in Q1 2024.
- Net loss attributable to common shareholders increased by approximately $1.2 million from Q1 2024 to Q1 2025.
- The OnTarget study did not achieve statistical significance in the overall population, limiting the broader applicability of the results.
Greetings, and welcome to Jaguar Health's May 15, 2025, investor webcast. Before I turn the call over to management, I'd like to remind you that management may look -- forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, and product initiatives, including product development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information and management's current assumptions, expectations and projections about future events. While management believes its assumptions, expectations, and projections are reasonable in view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements.
The company's actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
